ArticleWorld journal of gastroenterology2022
Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease.
Article in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trends in the use of biologic agents and their persistence rates in inflammatory bowel disease in India.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- Health-related quality of life in IBD patients with long COVID under China's normalized COVID-19 management.BMC infectious diseases · 2026Article
- Use of medications to treat inflammatory bowel diseases before and during pregnancy in Switzerland between 2012 and 2019: an observational study using the claims-based MAMA cohort.BMC gastroenterology · 2026Observational
- Epidemiology and Steroid Dependency Reduction in Crohn's Disease During the Biologics Era: A Nationwide Population-Based Study.Advances in therapy · 2025Article
- Association of vitamin D and platelet-to-lymphocyte ratio in treatment escalation risk for newly diagnosed Crohn's disease adults.Nutrition journal · 2025Article
- Article
- Infliximab monitoring in Crohn's disease: a neural network approach for evaluating disease activity and immunogenicity.Therapeutic advances in gastroenterology · 2024Article
- Temporal trends in surgery for Crohn's disease: a ten-year single-center retrospective study.International journal of colorectal disease · 2023Article
- Geographical heterogeneity in the disease characteristics and management of patients with inflammatory bowel disease, the preliminary results of a Chinese database for IBD (CHASE-IBD).Therapeutic advances in gastroenterology · 2023Article
- Temporal Trends of Inflammatory Bowel Disease Burden in China from 1990 to 2030 with Comparisons to Japan, South Korea, the European Union, the United States of America, and the World.Clinical epidemiology · 2023Article
- Low-dose ganciclovir ameliorates dextran sulfate sodium-induced ulcerative colitis through inhibiting macrophage STING activation in mice.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedications for inflammatory bowel disease (IBD) have changed dramatically over time. However, no study on long-term medication profiles has been conducted in the Chinese population.
aimTo evaluate temporal changes in medication use and treatment patterns for Chinese patients with IBD.
methodsA multicenter retrospective cohort study was conducted among Chinese patients newly diagnosed with Crohn's disease (CD) and ulcerative colitis (UC) between January 1999 and December 2019. Baseline characteristics and drug prescriptions were collected. Trends in medication use and therapeutic patterns were analyzed.
resultsIn total, 3610 patients were analyzed. During follow-up, 5-aminosalicylates (5-ASA) and corticosteroids (CS) prescriptions gradually decreased, accompanied by a notable increase in immunosuppressants (IMS) and infliximab (IFX) prescriptions in patients with CD. Prescription rates of 5-ASA and CS were stable, whereas IMS and IFX slightly increased since 2007 in patients with UC. Subgroup (
conclusionLong-term treatment strategies analyses has provided unique insight into the switch from conventional drugs to IFX in Chinese patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.